Cargando…

Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia

OBJECTIVE: To compare fertility-sparing therapies including oral progestogens, hysteroscopic resection (HR), and the levonorgestrel- releasing intrauterine system (LNG-IUS) in achieving disease regression, recurrence and live birth rate in well differentiate early-stage endometrial carcinoma (eEC) a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qing, Qi, Gonghua, Kanis, Margaux J., Dong, Ruifen, Cui, Baoxia, Yang, Xingsheng, Kong, Beihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593673/
https://www.ncbi.nlm.nih.gov/pubmed/28915701
http://dx.doi.org/10.18632/oncotarget.17588
_version_ 1783263087691825152
author Zhang, Qing
Qi, Gonghua
Kanis, Margaux J.
Dong, Ruifen
Cui, Baoxia
Yang, Xingsheng
Kong, Beihua
author_facet Zhang, Qing
Qi, Gonghua
Kanis, Margaux J.
Dong, Ruifen
Cui, Baoxia
Yang, Xingsheng
Kong, Beihua
author_sort Zhang, Qing
collection PubMed
description OBJECTIVE: To compare fertility-sparing therapies including oral progestogens, hysteroscopic resection (HR), and the levonorgestrel- releasing intrauterine system (LNG-IUS) in achieving disease regression, recurrence and live birth rate in well differentiate early-stage endometrial carcinoma (eEC) and complex atypical hyperplasia(CAH). STUDY DESIGN: This was a meta-analysis of previous studies focus on the fertility-sparing therapy for well differentiate early-stage endometrial carcinoma (eEC) and complex atypical hyperplasia (CAH). DATE SOURCES: Medline, the Cochrane Library and Embase was searched with the terms and Synonyms: words similar to eEC and CAH with therapies associated with fertility-sparing. MAIN OUTCOME MEASURES: The number of all patients accepted fertility sparing therapies, patients got regressed, relapsed and delivered were extracted from each study, and the regression, recurrence, and live birth rate of each study were calculated. The regression, recurrence and live birth rates between each two interventions were compared with the aid of meta-regression in packages of “meta” and ”meta for” written in R. RESULTS: Fifty-four studies reported fertility sparing therapies in young women with eEC and CAH were included. Meta-analysis showed that HR followed by progestogens achieved a higher pooled regression (98.06% vs 77.20% P < 0.0001) and live birth rate (52.57% vs 33.38%, P = 0.0944) and a lower recurrence rate compared with oral progestogens alone (4.79% vs 32.17% P = 0.0004). At the same time, the pooled live birth rate (52.57% vs 18.09% P =0.0399) of HR followed by progestogens are significantly higher than the LNG-IUS alone. Which no statistical difference in regression (98.06% vs 94.24%; P = 0.4098) and recurrence rates (4.79% vs 3.90% P = 0.8561) was seen. CONCLUSIONS: Of the available fertility-sparing therapeutic options, HR followed by progestogens may be a more effective one.
format Online
Article
Text
id pubmed-5593673
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-55936732017-09-14 Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia Zhang, Qing Qi, Gonghua Kanis, Margaux J. Dong, Ruifen Cui, Baoxia Yang, Xingsheng Kong, Beihua Oncotarget Review OBJECTIVE: To compare fertility-sparing therapies including oral progestogens, hysteroscopic resection (HR), and the levonorgestrel- releasing intrauterine system (LNG-IUS) in achieving disease regression, recurrence and live birth rate in well differentiate early-stage endometrial carcinoma (eEC) and complex atypical hyperplasia(CAH). STUDY DESIGN: This was a meta-analysis of previous studies focus on the fertility-sparing therapy for well differentiate early-stage endometrial carcinoma (eEC) and complex atypical hyperplasia (CAH). DATE SOURCES: Medline, the Cochrane Library and Embase was searched with the terms and Synonyms: words similar to eEC and CAH with therapies associated with fertility-sparing. MAIN OUTCOME MEASURES: The number of all patients accepted fertility sparing therapies, patients got regressed, relapsed and delivered were extracted from each study, and the regression, recurrence, and live birth rate of each study were calculated. The regression, recurrence and live birth rates between each two interventions were compared with the aid of meta-regression in packages of “meta” and ”meta for” written in R. RESULTS: Fifty-four studies reported fertility sparing therapies in young women with eEC and CAH were included. Meta-analysis showed that HR followed by progestogens achieved a higher pooled regression (98.06% vs 77.20% P < 0.0001) and live birth rate (52.57% vs 33.38%, P = 0.0944) and a lower recurrence rate compared with oral progestogens alone (4.79% vs 32.17% P = 0.0004). At the same time, the pooled live birth rate (52.57% vs 18.09% P =0.0399) of HR followed by progestogens are significantly higher than the LNG-IUS alone. Which no statistical difference in regression (98.06% vs 94.24%; P = 0.4098) and recurrence rates (4.79% vs 3.90% P = 0.8561) was seen. CONCLUSIONS: Of the available fertility-sparing therapeutic options, HR followed by progestogens may be a more effective one. Impact Journals LLC 2017-05-03 /pmc/articles/PMC5593673/ /pubmed/28915701 http://dx.doi.org/10.18632/oncotarget.17588 Text en Copyright: © 2017 Zhang et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Review
Zhang, Qing
Qi, Gonghua
Kanis, Margaux J.
Dong, Ruifen
Cui, Baoxia
Yang, Xingsheng
Kong, Beihua
Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia
title Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia
title_full Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia
title_fullStr Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia
title_full_unstemmed Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia
title_short Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia
title_sort comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593673/
https://www.ncbi.nlm.nih.gov/pubmed/28915701
http://dx.doi.org/10.18632/oncotarget.17588
work_keys_str_mv AT zhangqing comparisonamongfertilitysparingtherapiesforwelldifferentiatedearlystageendometrialcarcinomaandcomplexatypicalhyperplasia
AT qigonghua comparisonamongfertilitysparingtherapiesforwelldifferentiatedearlystageendometrialcarcinomaandcomplexatypicalhyperplasia
AT kanismargauxj comparisonamongfertilitysparingtherapiesforwelldifferentiatedearlystageendometrialcarcinomaandcomplexatypicalhyperplasia
AT dongruifen comparisonamongfertilitysparingtherapiesforwelldifferentiatedearlystageendometrialcarcinomaandcomplexatypicalhyperplasia
AT cuibaoxia comparisonamongfertilitysparingtherapiesforwelldifferentiatedearlystageendometrialcarcinomaandcomplexatypicalhyperplasia
AT yangxingsheng comparisonamongfertilitysparingtherapiesforwelldifferentiatedearlystageendometrialcarcinomaandcomplexatypicalhyperplasia
AT kongbeihua comparisonamongfertilitysparingtherapiesforwelldifferentiatedearlystageendometrialcarcinomaandcomplexatypicalhyperplasia